<DOC>
	<DOC>NCT00515268</DOC>
	<brief_summary>The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data from this study will be used to support GSK256066 dose selection for future studies in COPD patients.</brief_summary>
	<brief_title>Endotoxin Challenge Study For Healthy Men and Women</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide</mesh_term>
	<criteria>Healthy males and females (contraception restrictions), 1850yrs, BMI 1931kg/m2, Nonsmokers, FEV1 &gt;/= 80% predicted Abnormal troponin and/or CK MB, Participated in any GSK study involving the administration of COA for &gt;/= 21 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>LPS challenge,</keyword>
	<keyword>Healthy volunteers</keyword>
</DOC>